Veradermics, Incorporated

Veradermics, Incorporated EBIT per Share

The EBIT per Share of Veradermics, Incorporated (MANE) as of Oct 21, 2026 is -1.94 USD. In the previous year, EBIT per Share was -0.13 USD — a change of 1,356.74% (lower).

EBIT per Share

-1.94USD

YoY

1,356.74%

Last updated:

EBIT per Share of Veradermics, Incorporated is 2025 -1.94 USD. EBIT per Share of Veradermics, Incorporated was 2024 -0.13 USD. It decreases by 1,356.74% lower compared to the previous year.

The Veradermics, Incorporated EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2023
-0.09 USD
Jan 1, 2024
-0.13 USD
Jan 1, 2025
-1.94 USD
Jan 1, 2026 (e)
0.00 USD
Jan 1, 2027 (e)
-2.46 USD
Jan 1, 2028 (e)
-1.66 USD
Jan 1, 2029 (e)
-0.43 USD
Jan 1, 2030 (e)
5.30 USD
The Veradermics, Incorporated EBIT per Share history
YEAREBIT per ShareYoY
est5.30USD-1,335.65%
est-0.43USD-74.18%
est-1.66USD-32.59%
est-2.46USD—
est0.00USD-100.00%
-1.94USD+1,356.74%
-0.13USD+54.57%
-0.09USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Veradermics, Incorporated Stock analysis

What does Veradermics, Incorporated do? Veradermics, Incorporated develops novel therapeutics for dermatologic and aesthetic conditions, focusing on treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy, and VDMN, a dissolvable microarray patch technology for immunotherapy of common warts. VDAA targets alopecia areata, while VDMC addresses molluscum contagiosum. These products are used for treating androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in adult and pediatric populations, as well as the broader medical and clinical research community in dermatology. The company's revenue streams are derived from partnerships with healthcare providers and clinical research organizations for product development and clinical trials. These collaborations enable Veradermics to advance its pipeline of treatments, including VDPHL01, VDMN, VDAA, and VDMC, toward regulatory approval and commercialization. The primary buyers of Veradermics' services are healthcare providers and clinical research organizations involved in dermatology, with a focus on adult and pediatric dermatologic care and research. Veradermics operates within the clinical-stage biopharmaceutical sector, targeting dermatologic and aesthetic conditions. Its products are designed for specific conditions such as androgenetic alopecia, common warts, molluscum contagiosum, and alopecia areata, serving both adult and pediatric patient segments. The company's development activities are supported by partnerships with healthcare providers and clinical research organizations, which provide the necessary expertise and infrastructure for clinical trials and product advancement. Veradermics, Incorporated is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Veradermics, Incorporated stock

EBIT per Share of Veradermics, Incorporated is -1.94 USD in 2025.

EBIT per Share of Veradermics, Incorporated changed from -0.13 USD to -1.94 USD, representing a 1,356.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Veradermics, Incorporated since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Veradermics, Incorporated

All Key Metrics — Veradermics, Incorporated